A cross-sectional, national, multicenter, survey-based study to assess the effectiveness of Risk Minimization Measures related to Depakine® (sodium valproate) in Saudi Arabia. The study duration will be 7 months from 30 November 2024 to 30 May 2025. The end of study is defined as the end of the data collection period. No intervention will be administered, and no study related visits are required.

Start Date15 Mar 2025

Sponsor / Collaborator

Sanofi

CTR20244560

/ RecruitingNot Applicable

仁和堂药业有限公司研制的丙戊酸钠片（规格：0.2 g）与Kyowa Hakko Kirn Co., Ltd.持证的丙戊酸钠片（规格：0.2 g，Depakene®）在中国健康受试者中进行的单中心、随机、开放、单剂量、两序列、四周期、完全重复交叉设计空腹与餐后状态下的生物等效性研究

[Translation] A single-center, randomized, open-label, single-dose, two-sequence, four-period, completely repeated crossover design bioequivalence study of sodium valproate tablets (0.2 g) developed by Renhetang Pharmaceutical Co., Ltd. and sodium valproate tablets (0.2 g, Depakene®) licensed by Kyowa Hakko Kirn Co., Ltd. in healthy Chinese subjects under fasting and fed conditions

以仁和堂药业有限公司研制的丙戊酸钠片（规格：0.2 g）为受试制剂，Kyowa Hakko Kirn Co., Ltd.持证的丙戊酸钠片（规格：0.2 g，Depakene®）为参比制剂，考察两制剂在空腹与餐后状态下单次给药的药代动力学参数及相对生物利用度，评价两制剂是否具有生物等效性。同时评价两种制剂在健康人体中的安全性和耐受性。

[Translation]

The sodium valproate tablets (specification: 0.2 g) developed by Renhetang Pharmaceutical Co., Ltd. were used as the test preparation, and the sodium valproate tablets (specification: 0.2 g, Depakene®) certified by Kyowa Hakko Kirn Co., Ltd. were used as the reference preparation. The pharmacokinetic parameters and relative bioavailability of the two preparations were investigated in the fasting and postprandial states, and the bioequivalence of the two preparations was evaluated. At the same time, the safety and tolerability of the two preparations in healthy humans were evaluated.

Start Date16 Dec 2024

Sponsor / Collaborator

Shandong Province Renhetang Pharmaceutical Co. Ltd.

IRCT20240621062198N1

/ RecruitingPhase 2IIT

Comparing the Effect of Sodium valproate with Lithium carbonate on Suicidal Ideation of Patients with Bipolar Disorder in Manic Phase with Mediation of Interoception

Start Date22 Oct 2024

Sponsor / Collaborator

Mashhad University of Medical Sciences

100 Clinical Results associated with Sodium Valproate

100 Translational Medicine associated with Sodium Valproate

100 Patents (Medical) associated with Sodium Valproate

6,309

Literatures (Medical) associated with Sodium Valproate

01 Jun 2025·IBRO Neuroscience Reports

Potential of Khaya senegalensis to mitigate epileptogenesis and cognitive dysfunction on kainate-induced post-status epilepticus model

Article

Author: Kandeda, Antoine Kavaye ; Dimo, Théophile ; Foutse, Liliane Yimta ; Lewale, Stéphanie

Background and aimTo date, there is no treatment to prevent the development of temporal lobe epilepsy, the most common form of drug-resistant epilepsy. A recent study revealed the antiepileptic-like effect of the aqueous extract of Khaya senegalensis. Given the potential of this extract, the antiepileptogenic- and learning and memory-facilitating-like effects of the aqueous extract of Khaya senegalensis were assessed using the kainate-induced post-status epilepticus model.MethodsEpilepsy was induced by injecting a single dose of kainate (12 mg/kg, i.p.) in rats. Animals that developed 2 hours of status-epilepticus were randomized and treated as follows: a negative control group received distilled water (10 ml/kg, p.o.); two positive control groups received sodium valproate (300 mg/kg, p.o.) or phenobarbital (20 mg/kg, p.o.); and three test groups received the extract (50, 100, 200 mg/kg, p.o.). A sham group was added and received distilled water (10 ml/kg, p.o.). All treatments were performed twice daily until the occurrence of the first spontaneous seizure (stage 4 or 5) in the negative control group, on day 14. After the completion of treatments, memory impairment was assessed using the T-maze. Two weeks following behavioral analysis, the rats that received the most effective dose of the extract on spontaneous recurrent were challenged with pentylenetetrazole (30 mg/kg, i.p.). This is to assess their susceptibility to generalized tonic-clonic seizures (stage 5). Rats were finally euthanized, and pro-inflammatory cytokines, or neurogenesis markers were quantified in the hippocampus.ResultsThe extract of Khaya senegalensis significantly prevented spontaneous recurrent seizures on day 14. It also reduced cognitive decline. Furthermore, it significantly decreased pro-inflammatory cytokines levels and increased those of neurotrophic factors.ConclusionsThese findings thus suggest that the extract is endowed with antiepileptogenic- and learning and memory-enhancing-like effects. These effects are likely mediated by anti-inflammatory and neurotrophic pathways. This justifies, therefore, its use to treat empirically epilepsy.

10 Mar 2025·ACS Biomaterials Science & Engineering

Fabrication of Oro-Dispersible Sodium Valproate-Loaded Nanofibrous Patches for Immediate Epileptic Innervation

Article

Author: Parviz, Gita ; Ayyildiz, Simge ; Demirbas, Sinem G. ; Yekeler, Humeyra B. ; Ozcan, Gul S. ; Guler, Ece ; Ozdemir Kumral, Zarife N. ; Uner, Burcu ; Kalaskar, Deepak ; Yazir, Yusufhan ; Cam, Muhammet E.

Epilepsy is one of the oldest neurological disorders discovered by mankind. This condition is firmly coupled with unprovoked seizures stimulated by irrepressible neuroelectrical blasts. Orally taken valproate family has been employed for prophylactic management; however, oral administration is not applicable for critical scenarios, thus calling for medication routes fulfilling necessities of immediate innervation. In order to address this shortcoming, sodium valproate entrapped in poly(ethylene oxide)/polyvinylpyrrolidone (PEO/PVP) nanofibrous patches was developed with the aim of sublingual drug delivery. Initially, the production process was designed and optimized via the central composite design (CCD). Nanofiber fabrication was accomplished with a novel device by using the pressurized gyration method. Fabricated biomaterials were chemically, spatially, and thermally inspected. The beanless and homogeneous appearance of both virgin and impregnated nanofibrous patches was morphologically demonstrated via scanning electron microscopy. Additionally, adequately oro-dispersed impregnated patches released more than 90% of their drug content in under a minute. Following in vitro cyto-safety assurance acquired through 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay on SH-SY5Y neuroblastoma cells, the protective antiepileptic effect of impregnated patches was affirmed in vivo via pentylenetetrazole kindled-induced Mus musculus animal modeling. The parameter of in vivo behavioral evaluation was the Racine scoring system. Moreover, histopathological distinctions detected between different test groups were highlighted via fluorescence staining. Finally, the oxidative stress was determined according to quantitative variations of malondialdehyde, glutathione, superoxide dismutase, and catalase levels. The overall conclusion herein suggests that sodium valproate-loaded PEO/PVP nanofibrous patches strikingly prevented behavioral, structural, and oxidative deteriorations caused by pentylenetetrazole.

01 Mar 2025·Molecular Neurobiology

The Interactions of Resveratrol and Sodium Valproate on Penicillin-Induced Epilepsy Model: Electrophysiological and Molecular Study

Article

Author: Tosun, Nazan Goksen ; Nacar, Tuncer ; Kasap Acungil, Zeynep ; Tayhan, Secil Erden

Epilepsy represents the most prevalent chronic neurological disease, characterized by spontaneous recurrent seizures. In experimental epilepsy models created by different methods, resveratrol has been demonstrated to reduce epileptiform activity and exhibit neuroprotective properties. A penicillin-induced model of epileptogenesis was used to investigate the effects of resveratrol and its combination with sodium valproate on epileptiform activity. The study design was an in vivo animal experimental study. Forty Wistar-albino rats were divided into five groups, each with eight rats. The groups are categorized as the saline group, penicillin group (only penicillin), resveratrol group, sodium valproate group, and resveratrol + sodium valproate group. ECoG recording was taken for 180 min in all groups and statistically evaluated. GABAα1, mGluR1/mGluR5, NMDAR1 receptor expressions in the hippocampus, and S100B level in serum were measured. The spike frequency decreased statistically to 60th min in the sodium valproate group and 150th min in the resveratrol group. The spike frequency decreased statistically in the 20th min and later measurements of the recording in the resveratrol + sodium valproate group. GABAα1 receptor expression was increased in all groups compared to the penicillin group. mGluR1/mGluR5, NMDAR1 receptor expression was decreased in all groups compared to the penicillin group. Serum S100B level increased in all groups compared to the penicillin group. There was no statistically significant difference in epileptiform activity when resveratrol alone was administered in the penicillin-induced epilepsy model. Resveratrol co-administered with sodium valproate significantly reduced epileptiform activity. Co-administration of the sodium valproate + resveratrol group made the receptor level's highest GABAα1receptor expression at receptors.

News (Medical) associated with Sodium Valproate

11 Feb 2025

·cerenoscientific.com

Cereno Scientific’s HDACi CS014 has successfully completed part one of its Phase I trial evaluating the safety profile with a single ascending dose (SAD) study

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that drug candidate CS014 has completed the first part of two in its Phase I trial in healthy volunteers without any safety concerns. CS014 is a novel histone deacetylase (HDAC) inhibitor with disease-modifying potential being developed for the rare disease idiopathic pulmonary fibrosis (IPF). The Phase I trial intends to evaluate the safety profile of CS014 in humans and is divided into two parts – a single ascending dose part (SAD) and a multiple ascending dose part (MAD). Part two of the trial (MAD) is currently ongoing according to plan and the Phase I trial is expected to be completed in mid-2025. HDACi CS014 has the potential to transform the treatment landscape of IPF. Drug candidate CS014 is a new chemical entity that acts through HDACi with strong vascular remodeling effects and disease-modifying potential as seen in preclinical studies. The potential of the HDACis has been demonstrated through preclinical studies including reversal of pathological remodeling of pulmonary vessels and anti-fibrotic effects in an animal model of PAH, as well as in vivo anti-thrombotic effects across a broad range of vasculature. These properties align with the key disease mechanisms of idiopathic pulmonary fibrosis (IPF) and addresses significant unmet medical needs. The HDACi CS014 has a safety and efficacy profile that is consistent with the significant medical needs remaining despite current IPF treatments. Part one of the Phase I trial of CS014 conducted by our CRO partner CTC in Uppsala explored the safety, tolerability and pharmacokinetics (PK) of single ascending oral doses (SAD) of CS014 in 30 patients. This first part of the trial has successfully been completed with results showing that CS014 exhibited an acceptable safety profile supporting its potential for further clinical development. “We are pleased with the progress of the CS014 Phase I trial and eagerly anticipate its completion in mid-2025. The successful completion of the single ascending dose (SAD) part provides a strong initial validation of HDACi CS014s favorable safety profile,” said Rahul Agrawal, CMO & Head of R&D of Cereno Scientific. “We believe that our novel HDACi CS014 has the potential to become an important treatment meeting high unmet clinical needs in the rare disease IPF. There is a void in the market for safe and well-tolerated novel drugs with a profile addressing the underlying pathophysiology of the IPF disease and its progression. CS014 aims to be a safe, well-tolerated oral drug with disease-modifying capacity and, as such, targets a large market potential,” said Sten R. Sörensen, CEO of Cereno Scientific. The Phase I trial is an open-label, first-in-man trial designed to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending oral doses of CS014 in healthy volunteers. The Phase I trial of CS014 will involve approximately 48 subjects and is expected to be completed mid-2025 whereafter top-line results can be shared after data analysis has been conducted. For further information, please contact: Tove Bergenholt, Head of IR & Communications Email: tove.bergenholt@cerenoscientific.com Phone: +46 73- 236 62 46 Sten R. Sörensen, CEO Email: sten.sorensen@cerenoscientific.com Phone: +46 73-374 03 74 About CS104 HDAC inhibitor CS014 is a new chemical entity with a multi-modal mechanism of action as an epigenetic modulator, under development for idiopathic pulmonary fibrosis (IPF). An ongoing Phase I trial evaluating the safety, tolerability, pharmacokinetics, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending oral doses of CS014 in healthy volunteers is expected to conclude in mid-2025. Preclinical studies of HDAC inhibitors show that these drugs can reverse fibrosis in models of IPF. Studies also show that these drugs prevent the pathological remodeling of pulmonary vessels that ultimately leads to pulmonary hypertension in many IPF patients. Preclinical studies of CS014 have demonstrated an effect on reversal of fibrosis and a dose-dependent beneficial effect on pathological vascular remodeling in an established model of PAH. Together, these findings indicate that CS014 has the potential to address the underlying pathophysiology behind the development of IPF. CS014 has demonstrated, in preclinical studies, the ability to regulate platelet activity, local fibrinolysis, and clot stability, helping to prevent thrombosis without increasing the risk of bleeding. This supports CS014's potential to address key unmet needs in IPF patients. Cereno’s HDAC inhibitor portfolio, capitalizing on the principle of epigenetic modulation, comprises Cereno’s lead drug candidate CS1 in Phase II and CS014. About Cereno Scientific AB Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as a safe, effective and disease modifying treatment for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1’s safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 was safe, well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. HDACi CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 employs a multi-modal mechanism of action as an epigenetic modulator, targeting key unmet needs in patients with rare disease Idiopathic Pulmonary Fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Certified Adviser is Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com. Read PDF Share

Phase 1Clinical ResultPhase 2

27 Dec 2024

·cerenoscientific.com

Cereno Scientific has enrolled 9 additional patients in its Expanded Access Program with CS1 providing more long-term safety and efficacy data in rare disease PAH

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that 9 additional patients have entered its Expanded Access Program (EAP) with drug candidate CS1 in rare disease pulmonary arterial hypertension (PAH). In total, the EAP now includes 10 patients with the possibility of more patients being included in the coming months. The additional data collected on the patients in the EAP will strengthen the long-term safety and efficacy documentation of CS1 and support regulatory interactions for future clinical trials. “We are very pleased to see the high interest from patients and physicians to continue with the treatment of CS1 after the completed Phase IIa study,” said Sten R. Sörensen, CEO, Cereno Scientific. “From a drug development perspective, it is very valuable for us to be able to collect long-term clinical data on CS1 as we move forward with our plans for the next clinical program.” Drug candidate CS1 has been approved by the FDA for an Expanded Access Program as an extension of the Phase IIa trial in PAH. This program allows patients who have completed the Phase IIa trial to continue CS1 treatment if deemed suitable by physicians in the study. Through the recently entered collaboration with innovative medical company Fluidda, their non-invasive imaging technology called Functional Respiratory Imaging (FRI) will be used on certain patients enrolled in the EAP to visualize how long-term use of CS1 influences changes in pulmonary arteries. The EAP, an FDA-approved protocol, enables Cereno to obtain valuable long-term safety and efficacy data of CS1 in PAH patients supporting required regulatory interactions and planning future Phase IIb or pivotal Phase III trials. For further information, please contact: Tove Bergenholt, Head of IR & Communications Email: tove.bergenholt@cerenoscientific.com Phone: +46 732- 33 62 46 Sten R. Sörensen, CEO Email: sten.sorensen@cerenoscientific.com Phone: +46 73-374 03 74 About CS1 Drug candidate CS1 is an HDAC inhibitor (HDACi) that works through epigenetic modulation, being developed as a safe, effective and disease-modifying treatment for the rare disease pulmonary arterial hypertension (PAH). CS1 targets the root mechanism of the disease, aiming to reverse the pathological vascular remodeling of the small lung arteries. In a Phase IIa study, CS1 successfully met the primary endpoint of safety and tolerability. CS1 further showed compelling positive impact on exploratory clinical efficacy parameters over the 12-week treatment period. The Phase IIa data, together with preclinical data from the HDACi program, directly demonstrates the HDACi program’s dose-dependent positive impact on reverse remodeling in small lung arteries. This provides a basis of assumption that CS1 may act with disease-modifying capacity in PAH. In preclinical cardiovascular disease models, HDAC inhibitors have also shown anti-fibrotic, anti-inflammatory, pulmonary pressure-reducing, and anti-thrombotic effects. CS1’s unique efficacy profile aligns well with the underlying mechanisms of disease that drives the progression of PAH, positioning it to address the critical unmet need for more effective treatment options. The goal of CS1's development is to enhance and extend life for patients with PAH. CS1 is part of Cereno’s HDACi portfolio, untapping the potential of epigenetic modulation in rare cardiovascular and pulmonary diseases. CS1 has been granted orphan drug status in both the US and EU. CS1 has been approved by the FDA for an Expanded Access Program (EAP) as an extension of the Phase IIa trial in PAH, which enables Cereno to obtain valuable long-term safety and efficacy data of CS1 in PAH patients. Ten patients are currently enrolled in the program, which allows patients who have completed the Phase IIa trial to continue CS1 treatment if deemed suitable by physicians in the study. Through a collaboration with innovative medical company Fluidda, their non-invasive imaging technology called Functional Respiratory Imaging (FRI) will be used on certain patients enrolled in the EAP to visualize how long-term use of CS1 influences changes in pulmonary arteries. The data obtained by the EAP supports required regulatory interactions and planning future Phase IIb or pivotal Phase III trials. About Cereno Scientific AB Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as a safe, effective and disease modifying treatment for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1’s safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 was safe, well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. HDACi CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 employs a multi-modal mechanism of action as an epigenetic modulator, targeting key unmet needs in patients with rare disease Idiopathic Pulmonary Fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Certified Adviser is Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com. Read PDF Share

Phase 2Phase 1Clinical ResultOrphan Drug

20 Dec 2024

·cerenoscientific.com

Cereno Scientific announces that the registration of warrants and convertibles to Fenja and Arena has been completed and that delivery of the warrants has been initiated

20 Dec 2024 07:00Regulatory Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, announced on 11 November 2024 that the Company has entered into a financing agreement (the “Financing Agreement”) with Fenja Capital II A/S and the US-based investor Arena Investors, LP (the “Financiers”) securing loan financing of at least 250 MSEK. The Financing Agreement is divided into three components: (i) a cash loan in two tranches totaling 175 MSEK (the “Loan”), (ii) the issue of convertible loans of 75 MSEK to the Financiers (the “Convertibles”), and (iii) the issue without consideration of 5,749,017 warrants to the Financiers (the “Warrants”). The Company today announce that the Convertibles and the Warrants have been registered with the Swedish Companies Registration Office and that the transfer of the Warrants to the Financiers’ custody accounts has been initiated. Completed registration and ongoing delivery The Company hereby announces that the Convertibles and the Warrants have been registered with the Swedish Companies Registration Office and that the delivery of the Warrants following their connection to Euroclear has been initiated to the custody accounts designated by the Financiers. Main terms of the Convertibles, the Warrants and the Loan The convertible loans of 75 MSEK is represented by convertible promissory notes in the nominal amount of SEK 1 per Convertible. The Convertibles will be due for repayment on 30 April 2026 (the "Maturity Date"), unless Conversion has occurred before that date. The rate of interest on the Convertibles are calculated quarterly and determined at the percentage rate per annum which is the aggregate of STIBOR90 with an additional 11 percentage points. The Company has a right but no obligation to repay the Convertibles, in whole or in part, at any time prior to the Maturity Date without separate costs. In connection with any premature repayment, accrued interest of the amount so prepaid should be paid at the same time. During the term of the Convertibles, the Financiers may demand conversion of all or part of the Convertibles into new B shares in the Company at a conversion price fixed at SEK 6.09. Presuming full conversion of the Convertibles the number of shares in Cereno Scientific will increase by 12,315,270 B-shares and the share capital will increase by SEK 1,231,527 corresponding to a dilution effect of approximately 4.19 per cent of the currently outstanding shares in the company and approximately 4.10 per cent of the currently outstanding votes in the company. In relation to the Warrants, the Financiers are entitled to subscribe for one new B share for each Warrant at a subscription price of SEK 6.82 per B share during the term of the Warrants (up to and including 8 November 2029). Exercise of the Warrants can be done during the whole term of the Warrants. Upon full exercise of the Warrants, the company will receive additional issue proceeds of approximately 39.2 MSEK. Presuming full exercise of the Warrants, the number of shares in Cereno Scientific will increase by 5,749,017 B-shares and the share capital will increase by SEK 574,901.70 corresponding to a dilution effect of approximately 2.00 per cent of the currently outstanding shares in the company and 1.96 per cent of the currently outstanding votes in the company. The Loan is divided into two tranches where Tranche 1 consists of a cash loan of 125 MSEK which was paid out in connection with the signing of the Financing Agreement. Tranche 2 consists of a cash loan of 50 MSEK and is conditional upon the Company having received approval by the FDA regarding CS1 for a phase IIB study or a pivotal study for phase III as well as certain additional financial conditions being fulfilled. The Loan was subject to a customary setup fee amounting to approximately 3,87 per cent of the funding under the Financing Agreement. Parts of Tranche 1 of the Loan have been used to repay the currently outstanding loan to Fenja of approximately 91 MSEK. The interest rate of the Loan under the Financing Agreement is fixed annually starting at the time of payment and bears an annual interest rate set at the percentage rate per annum which is the sum of STIBOR plus 11 percentage points. Repayment of the Loan (both Tranches, if applicable) shall be made on 30 April 2026. Further fundamental information about the Convertibles, the Warrants and the Financing Agreement can be found in the press release of 11 November 2024: Press release | Cereno Scientific. For further information, please contact: Eva Jagenheim, CFO Email: eva.jagenheim@cerenoscientific.com Phone: +46 70 492 35 63 Sten R. Sörensen, CEO Email: sten.sorensen@cerenoscientific.com Phone: +46 73-374 03 74 About Cereno Scientific AB Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as a safe, effective and disease modifying treatment for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1’s safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 was safe, well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. HDACi CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 employs a multi-modal mechanism of action as an epigenetic modulator, targeting key unmet needs in patients with rare disease Idiopathic Pulmonary Fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Certified Adviser is Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information at www.cerenoscientific.com. Read PDF Share

Phase 1Phase 2Clinical Result

100 Deals associated with Sodium Valproate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Sodium Valproate	N03AG01	DBSALT001257

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Nervous System Diseases	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	01 Jan 1982
Bipolar Disorder	Japan	Sumitomo Pharma Co., Ltd.	01 Sep 1981
Migraine Disorders	Japan	Sumitomo Pharma Co., Ltd.	01 Sep 1981
Epilepsy	Japan	Kyowa Kirin Co., Ltd.	24 May 1974

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Epilepsy	Phase 1	China	Lizhuo Pharmaceutical (Xiamen) Co., Ltd.	10 Oct 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05224531 (CS1-003, PipelineReview) Manual	Phase 2	Pulmonary Arterial Hypertension	21	CS1	lwhrpzzqwy(vtooserkct) = rqstcchbro qwcisdprjl (jqcqmkevdw ) View more	Positive	29 Sep 2024
NCT04698525 (CTgov)	Phase 3	Migraine Disorders	33	Valproate Sodium (Valproate Group)	bneghhkzbr(wtnxtmazbo) = mwbgfyxsxa kyilzzzlsm (lbasnfegkb, wfvxjlnnhc - soxaibaovv) View more	-	17 May 2023
				memantine (Memantine)	bneghhkzbr(wtnxtmazbo) = sqpditxnxd kyilzzzlsm (lbasnfegkb, ytmvivjwkl - wmuomnxzou) View more
CTRI/2020/01/022781 (ESMO_ASIA2022)	Phase 2	Platinum-Resistant Ovarian Carcinoma	27	Oral etoposide + Sodium valproic acid (VPA)	(qzwxvmksva) = zkhetgfewp bxjyhrjgch (zmrbvqcghh ) View more	-	03 Dec 2022
IEC2017	Not Applicable	Status Epilepticus	100	Sodium Valproate	edvxnmkduk(hftmkutchi) = wsfmdpqdhr dsbvcisboh (mdpsnsnste ) View more	Positive	03 Sep 2017
				Levetiracetam	wstzwhzwmb(fatawlulnh) = erymqobrkp jnqxjdyapp (atqkkcmxcs )
IAS2017	Not Applicable	-	-	Manα1-2Man-binding lectins (GRFT, CV-N, and SV-N)	vbuwugumwd(cugvfbqght) = ptnqtkdagw epuuqvlioa (vtciaeuihq )	-	01 Jan 2017
IRCT201202199014N1 (Pubmed \| PLoS One)	Phase 3	Migraine Disorders	104	Intravenous sodium valproate	fqpqcolftv(dtfbkoidjp) = aoizhcwkip jzpnbashsz (pjcepbquhd )	-	01 Jan 2015
				Intravenous dexamethasone	fqpqcolftv(dtfbkoidjp) = odeikdupqm jzpnbashsz (pjcepbquhd )
IEC2013	Not Applicable	Seizures	53	Carbamazepine	gxfsbufgke(lxyielpsrd) = Female patients had lower QOLIE score. The older patients have low QOLIE score. pooxnkydwr (yimmujmykt )	Positive	24 Jun 2013
				Sodium Valproate
IEC2013	Not Applicable	Status Epilepticus	364	Intravenous sodium valproate	gspazfnsid(auezorbqnp): RR = 1.07 (95% CI, 0.91 - 1.24)	Negative	24 Jun 2013
				Intravenous phenytoin
NCT00203242 (CTgov)	Not Applicable	Cluster Headache	15	Depakote+Depacon IV	auepqlsdox(wfizjonfqg) = mpgzvhmkxt hhuszmavdm (qrydmjbhuk, dgfpeontzz - swwzwyqvpl) View more	-	06 Jul 2011

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis